<DOC>
	<DOC>NCT00660881</DOC>
	<brief_summary>The primary objective of the study is to assess the safety of epratuzumab in patients with SLE.</brief_summary>
	<brief_title>Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>SL0007 patients who completed through week 12 of the study or who early terminated at week 8 or later due to treatment failure Patients must have maintained eligibility requirements throughout their participation in SL0007 Written informed consent signed prior to initiation of any studyspecific assessments at visit 1 Patients may not receive any live vaccination within 2 weeks prior to visit 1 or during the course of the study Active severe SLE disease activity which involves the CNS system (defined by BILAG neurologic A level activity) including transverse myelitis, psychosis and seizures Active severe SLE disease activity which involves the Renal system (defined by BILAG renal level A activity or Grade III or higher WHO nephritis) or serum creatinine &gt;2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks or proteinuria &gt;3.5gm/day Patients with a history of antiphospholipid antibody syndrome AND Use of oral anticoagulants or antiplatelet treatment Patients with a history of chronic infection, recent significant infection, or any current sign of symptom that may indicate an infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-Cell immunotherapy</keyword>
</DOC>